-
1
-
-
0036293243
-
Global control of hepatitis B virus infection
-
Kao JH, Chen DS. Global control of hepatitis B virus infection. Lancet Infect. Dis. 2002; 2: 395-403.
-
(2002)
Lancet Infect. Dis.
, vol.2
, pp. 395-403
-
-
Kao, J.H.1
Chen, D.S.2
-
2
-
-
59749096640
-
Hepatitis B virus infection
-
Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009; 373: 582-592.
-
(2009)
Lancet
, vol.373
, pp. 582-592
-
-
Liaw, Y.F.1
Chu, C.M.2
-
3
-
-
0027422748
-
From hepatitis to hepatoma: lessons from type B viral hepatitis
-
Chen DS. From hepatitis to hepatoma: lessons from type B viral hepatitis. Science 1993; 262: 369-370.
-
(1993)
Science
, vol.262
, pp. 369-370
-
-
Chen, D.S.1
-
4
-
-
0348047588
-
Hepatitis B virus genotypes and hepatocellular carcinoma in Taiwan
-
Kao JH. Hepatitis B virus genotypes and hepatocellular carcinoma in Taiwan. Intervirology 2003; 46: 400-407.
-
(2003)
Intervirology
, vol.46
, pp. 400-407
-
-
Kao, J.H.1
-
5
-
-
84865376141
-
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update
-
Liaw YF, Kao JH, Piratvisuth T etal. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol. Int. 2012; 6: 531-561.
-
(2012)
Hepatol. Int.
, vol.6
, pp. 531-561
-
-
Liaw, Y.F.1
Kao, J.H.2
Piratvisuth, T.3
-
6
-
-
84862664371
-
EASL clinical practice guidelines: management of chronic hepatitis B virus infection
-
European Association for the Study of the Liver
-
European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J. Hepatol. 2012; 57: 167-185.
-
(2012)
J. Hepatol.
, vol.57
, pp. 167-185
-
-
-
7
-
-
70349240414
-
Chronic hepatitis B: update 2009
-
Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662.
-
(2009)
Hepatology
, vol.50
, pp. 661-662
-
-
Lok, A.S.1
McMahon, B.J.2
-
8
-
-
80051498209
-
Recent advances in the treatment of chronic hepatitis B
-
Lin CL, Kao JH. Recent advances in the treatment of chronic hepatitis B. Expert Opin. Pharmacother. 2011; 12: 2025-2040.
-
(2011)
Expert Opin. Pharmacother.
, vol.12
, pp. 2025-2040
-
-
Lin, C.L.1
Kao, J.H.2
-
9
-
-
84897612861
-
-
National Health Insurance Administration Ministry of Health and Welfare. Taiwan reimbursement guideline for hepatitis B agents. Cited 27 March 2013. Available from URL. Sections 7.3 and 7.4, Chapter 10.
-
National Health Insurance Administration Ministry of Health and Welfare. Taiwan reimbursement guideline for hepatitis B agents. 2013. Cited 27 March 2013. Available from URL: http://www.nhi.gov.tw/webdata/webdata.aspx?menu=18&menu_id=683&webdata_id=2919&WD_ID=756. Sections 7.3 and 7.4, Chapter 10.
-
(2013)
-
-
-
10
-
-
0032499913
-
One year trial of lamivudine for chronic hepatitis B
-
Lai CL, Chien RN, Leung Nancy WY etal. One year trial of lamivudine for chronic hepatitis B. N. Engl. J. Med. 1998; 339: 61-68.
-
(1998)
N. Engl. J. Med.
, vol.339
, pp. 61-68
-
-
Lai, C.L.1
Chien, R.N.2
Leung Nancy, W.Y.3
-
11
-
-
0034235528
-
Effects of extended lamivudine treatment in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group
-
Liaw YF, Leung NW, Chang TT etal. Effects of extended lamivudine treatment in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000; 119: 172-180.
-
(2000)
Gastroenterology
, vol.119
, pp. 172-180
-
-
Liaw, Y.F.1
Leung, N.W.2
Chang, T.T.3
-
12
-
-
0033592764
-
Lamivudine as initial treatment for chronic hepatitis B in the United States
-
Dienstag JL, Schiff ER, Wright TL etal. Lamivudine as initial treatment for chronic hepatitis B in the United States. N. Engl. J. Med. 1999; 341: 1256-1263.
-
(1999)
N. Engl. J. Med.
, vol.341
, pp. 1256-1263
-
-
Dienstag, J.L.1
Schiff, E.R.2
Wright, T.L.3
-
13
-
-
58649096155
-
2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B
-
Liaw YF, Gane E, Leung N etal. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009; 136: 486-495.
-
(2009)
Gastroenterology
, vol.136
, pp. 486-495
-
-
Liaw, Y.F.1
Gane, E.2
Leung, N.3
-
14
-
-
35649020315
-
Entecavir treatment for up to 96 weeks in patients with HBeAg positive chronic hepatitis B
-
Gish RG, Lok AS, Chang TT etal. Entecavir treatment for up to 96 weeks in patients with HBeAg positive chronic hepatitis B. Gastroenterology 2007; 133: 1437-1444.
-
(2007)
Gastroenterology
, vol.133
, pp. 1437-1444
-
-
Gish, R.G.1
Lok, A.S.2
Chang, T.T.3
-
15
-
-
33644822860
-
Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B
-
Lai CL, Shouval D, Lok AS etal. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 2006; 354: 1011-1020.
-
(2006)
N. Engl. J. Med.
, vol.354
, pp. 1011-1020
-
-
Lai, C.L.1
Shouval, D.2
Lok, A.S.3
-
16
-
-
78649631236
-
Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B
-
Chotiyaputta W, Peterson C, Ditah FA, Goodwin D, Lok AS. Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B. J. Hepatol. 2011; 54: 12-18.
-
(2011)
J. Hepatol.
, vol.54
, pp. 12-18
-
-
Chotiyaputta, W.1
Peterson, C.2
Ditah, F.A.3
Goodwin, D.4
Lok, A.S.5
-
17
-
-
84875296320
-
Adherence to medication is a more important contributor to viral breakthrough in chronic hepatitis B patients treated with entecavir than in those with lamivudine
-
Kamezaki H, Kanda T, Arai M etal. Adherence to medication is a more important contributor to viral breakthrough in chronic hepatitis B patients treated with entecavir than in those with lamivudine. Int. J. Med. Sci. 2013; 10: 567-574.
-
(2013)
Int. J. Med. Sci.
, vol.10
, pp. 567-574
-
-
Kamezaki, H.1
Kanda, T.2
Arai, M.3
|